Scientific programme


Print Programme
  AUDITORIUM MEETING ROOM 1 MEETING ROOM 2 MEETING ROOM 3
09:30-10:45  

DERMOSCOPY COURSE PART I

 

G. Argenziano,S. Puig, P. Soyer

 

Speakers: C. Carrera, P. Zaballos,

I. Zalaudek

 

How I use Dermoscopy in my practise

G. Argenziano

Diagnosis of melanoma

S. Puig

Diagnosis of other tumours

P. Zaballos

Cases with clinic-histopathology

correlation

C.Carrera

Discussion: G. Argenziao, P. Soyer, S. Puig,

I. Zalaudek

International Dermoscopy Society Course
Presentation
Dermoscopy and clinical-pathologic correlation is essential in the management of skin cancer. The IDS in collaboration with the EADO and the World Melanoma Skin Cancer Centres Meeting propose a special course with medium and advanced contents that will cover the new advances in Dermoscopy and the discussion of clinical situations with pathology correlation. The course faculty is composed of relevant experts in the field and dermatopathologists who will provide a unique opportunity to enjoy a noteworthy experience.

   
10:45 - 11:00   Coffee break    
11:00-12:15  

DERMOSCOPY COURSE PART II

 

R. Hofmann-Wellenhof, H. Kittler, A .Lallas

 

Speakers: A. Barreiro, L. Ferrandiz,

C. Longo, I. Zalaudek

 

How I manage pink lesions

H. Kittler

How I manage facial lesions

R. Hofmann-Wellenhof

How I manage acral lesions

A. Lallas

Cases with clinic-histopathology

correlation

A. Barreiro, L. Ferrandiz

Discussion: R. Hofmann-Wellenhof, H. Kittler,

A. Lallas, C. Longo, I. Zalaudek

   
13:00-14:15

SIMPOSIUM 1

Controversies & new development in melanoma

Chairs: C. Garbe - J. Malvehy

 

Will the computers replace the dermatologist?

Yes: J.Malvehy; No: S. Puig

Is the pathology the right gold standard for melanoma?

Yes: L. Requena; No: P. Soyer

Is the new AJCC a progress?

Yes: J. E.Gershenwald; No: J.J. Grob

 

 

 

 

   
14:15-15:30

SIMPOSIUM 2

Controversies & open questions in melanoma

Chairs: V. Sondak - J. Thompson

 

We have biomarkers for treatment decisions

Yes: O. Michielin; No: C. Blank

Do we still need surgery in advanced melanoma?

Yes: J. Thompson; No: J. Larkin

Do we still need target therapy in the age of immunotherapy?

Yes: D. Schadendorf; No: TBD

     
15:30-16:00 Coffee break - visit to the Exhibition & e-poster viewing
16:00-17:00

INDUSTRY SATELLITE SYMPOSIUM

SANOFI GENZYME + REGENERON

Unlocking the potential of

immuno-oncology in

advanced cutaneous

squamous cell carcinoma

(CSCC): role of checkpoint blockade

 

Welcome and introduction

S. Puig

 

Understanding CSCC . disease overview, epidemiology, risk factors

S. Puig

 

Existing treatment approaches for the management of advanced CSCC

E. Stockfleth

 

Future novel therapeutic strategies, including checkpoint blockade, for advanced CSCC

M. Migden

 

Q & A Discussion

S. Puig

 

Conclusions

S. Puig

     
17:00-17:15 OPENING CEREMONY      
17:15-17:45

OPENING KEYNOTE LECTURE

Chairs: H. Pehamberger  - J. Thompson

 

TBD

     
17:45-19:00 WELCOME RECEPTION      
  AUDITORIUM MEETING ROOM 1 MEETING ROOM 2 MEETING ROOM 3
08:00-09:00

SYMPOSIUM 3

Epidemiology of melanoma

Chairs: S. Gandini - J. J. Grob - D. Whiteman

 

The worldwide burden of skin cancer

S.Gandini
 

What should the public be told  about prevention?

J. J. Grob
 

Melanoma incidence:  signs for a decline?

D. Whiteman
 

Melanoma: differences and trends in Europe

A. M. Forsea

BREAKOUT SESSION 1

Skin cancer guidelines: International structure & cooperation

Chairs: C. Garbe - J. Thompson

BREAKOUT SESSION 2
Building & EADO registry

Chairs: U. Leiter-Stöppke -

M. Weichenthal

NURSES SESSION

Chairs: P. Iglesias - P. Mohr

 

Dermatological tumours and surgery

 

Chemotherapy and radiotherapy for dermatological patients

 

Practical course how to work with port systems

 

TKI and side effect management in melanoma and BCC

 

Immune oncology in melanoma/ merkel cell carcinoma and management of side effects

 

Adjuvant therapy in melanoma

09:00:10:00

SYMPOSIUM 4

Actinic keratoses

Chairs: K. Peris - A. Stratigos

 

Epidemiology and biology of actinic keratoses

A. Stratigos

 

Classification and grading of actinic keratoses

G. Pellacani

 

Topical treatment of actinic keratoses and field cancerization 

K. Peris

 

New developments in the photodynamic therapy of actinic keratoses

R. M. Szeimies

SYMPOSIUM 5

Genetics of melanoma

Chairs: E. Nagore - J. Newton-Bishop -

S. Puig

 

Genetic susceptibility to melanoma

T. Bishop

 

Familial melanoma

J. Newton-Bishop

 

Genetics and prognosis

E. Nagore

 

Genetics and treatment decision

S. Puig

 

WORKSHOP 1

Skin cancer prevention and screening

Chairs:  V. Del Marmol - A.M. Forsea

 

Skin cancer prevention - anything beyond protection? V. Bataille

 

Melanoma risk factors - new insights

V. del Marmol

 

Skin cancer early detection - what works? What can we do better?

A.M. Forsea

 

Consumer-apps for skin cancer prevention and detection - what can they really do?

P. Soyer

 

Skin cancer prevention & screening
Presentation
Although the new innovative therapies have recently brought a dramatic improvement to a long-time hopeless situation, the prevention and early detection of skin cancers remain crucial tools to reduce the burden of human and material costs induced by these frequent tumors.

We benefit nowadays from an explosion of new insights in the mechanisms of cutaneous oncogenesis and its risk factors, of development of the opto-spectral, non-invasive skin imaging techniques, and of evolving computer-assisted solutions for diagnosis. These are bound to shape and transform our approach to early detection and prevention in the near future.

This educational session aims to highlight the new evidence regarding major topics for skin cancer primary and secondary prevention. It aims to bring clinicians the top-new knowledge needed to guide their decisions in the every-day clinical practice for the optimal management of high-risk patients.

 

 
10:00-10:30 Coffee break - visit to the Exhibition & e-poster viewing
10:30-11:30

INDUSTRY SATELLITE SYMPOSIUM  

BRISTOL-MYERS SQUIBB

Translating science into progress: the future of melanoma treatment?

Chair: E. Muñoz

 

Welcome and introduction

E. Muñoz

 

PD-L1 and beyond: biomarker update

J. M. Piulats

 

Continuing innovation - new approaches for melanoma treatment

C. Höller

 

Summary and close

E. Muñoz

     
11:30-11:45

Report of BREAKOUT SESSIONS 1-2

Chairs: J. Malvehy  - U. Leiter-Stöppke -

J. Thompson

     
11:45-12:30

PLENARY LECTURES I

Chairs :

F. M. Camacho - G. Pellacani

 

Total body mapping, non-invasive diagnosis and AI systems in skin cancer detection

A. Halpern

 

How does UV induce skin cancer?

A. Virós
 

     
12:45-13:45

INDUSTRY SATELLITE LUNCH SYMPOSIUM

HELSINN HEALTHCARE

     
14:00-15:00  

SYMPOSIUM 6

Surgery and Neoadjuvancy therapy of melanoma

Chairs: R. Kaufman  - D. Moreno - V. Sondak

 

Standards and exceptions in surgery of primary melanomas

R. Kaufman

 

Sentinel lymph node biopsy and lymph node dissection. 

Are they still needed?

D. Moreno  

 

European approaches on SNB+/N+ melanoma patients

A. Testori 

 

Current and future role of neoadjuvant therapy

V. Sondak

SYMPOSIUM 7

New imaging diagnostic

Chairs: J. Malvehy - I. Zalaudek

 

 

Whats new in dermoscopy of skin cancer

I. Zalaudek

 

Digital imaging and beyond

J. Malvehy

 

Confocal microscopy and OCT in skin cancer diagnosis

G. Pellacani

 

Electrical impedanciometry in melanoma detection

R. Hofmann- Wellenhof  

 

 

 
15:15-16:15 INDUSTRY SATELLITE SYMPOSIUM -  MSD      
16:15-16:45 Coffee break - visit to he Exhibition & e-poster viewing
16:45-17:45

SYMPOSIUM 8

Adjuvant therapy in melanoma

Chairs: H. Gogas - J. Hassel

 

Adjuvant treatment of melanoma in the past

P. Mohr

 

Checkpoint Inhibition as adjuvant Treatment in melanoma

H. Gogas

 

BRAF/MEK Inhibition as adjuvant Treatment in melanoma

J. Hassel

 

Adjuvant vaccination strategies and future perspective

U. Sahin

 

SYMPOSIUM 9

Difficult to treat subtypes of melanoma

 

Chairs: P. Arenberger - C. Carrera -

L. Kandolf-Sekulovic

 

Update on treatment of lentigo maligna

C. Carrera

 

Update on treatment of mucosal melanoma

L. Kandolf Sekulovic

 

Management of melanoma in pregnancy

P. Arenberger

 

Management of melanoma in immunosuppressed patients

C. Lebbé

WORKSHOP 2

Dermatologic ultrasound in skin cancer patients

Chairs: F. Alfageme - P. Giavedoni

 

Dermatologic ultrasound: Practicalities and state of the art in skin oncology

P. Giavedoni

 

Multiparametric ultrasonographic assessment of non melanoma skin cancer

R. Badea

 

Ultrasonography for the follow up and prognosis of melanoma

L. Ferrándiz

 

New diagnostic approaches in dermatologic ultrasound of skin cancer: elastography, US contrasts and ex-vivo

F. Alfageme

 

Cases for the audience and discussion

Dermatologic Ultrasound in Skin Cancer Patients
Presentation
In skin cancer ultrasonography is a diagnostic tool that is integrated in the diagnostic armamentarium for the pre-surgical anatomic evaluation of the skin tumour, detection of local metastasis or recurrences of the tumour and for guided intralesional therapies among indications. With the recent introduction of new technical improvements US is evolving into an essential tool for the management of skin cancer patients in the hands of the Dermato-oncologists in collaboration with radiologists in skin cancer centres. This educational activity is devoted to professionals involved in the diagnosis and treatment of skin cancer patients from those that have no previous experience to those that are already experienced in US. This two hour training programme will include state of the art and future innovations of US in skin cancer patients with practical cases. Limited to 50 places.


FREE COMMUNICATIONS I:

Chairs: A. Barreiro -

M. Bylaitè-Bucinskiene
18:00-19:00

INDUSTRY SATELLITE SYMPOSIUM

SANOFI GENZYME + RENEGERON

     
  AUDITORIUM MEETING ROOM 1 MEETING ROOM 2 MEETING ROOM 3
08:00-09:00

SYMPOSIUM 10

Treatment of advanced BCC & SCC MELANOMA

Chairs: N. Basset-Seguin - A.Stratigos - R. Vieira

 

Classification of advanced BCC

J. J. Grob

 

Update in the management of HhI in the treatment of advanced BCC

N. Basset-Seguin

 

Management of advanced SCC

A. Stratigos

 

Surgical treatment in advanced tumours

R. Vieira

SYMPOSIUM 11 

Targeted therapy

Chairs: A. Arance - G. Long - D. Schadendorf

 

Issues in targeted therapy in BRAF mutant melanoma: Adjuvant therapy and which BRAF/MEK combination in the metastatic setting?

G. Long

 

NRAS mutant melanoma: Targeted therapy, are we there yet?

D. Schadendorf

 

Other targets in Melanoma

R. Dummer

 

Targets in non-cutaneous melanoma

A. Arance

BREAKOUT SESSION 3

Data management in melanoma

Chairs: J.E. Gershenwald -

S. Puig

 

 

 

 

 

 

 

 

 

 

BEAKOUT SESSION 4

Equitance & access to treatments in Europe

Chairs: A.M. Forsea - L. Kandolf Sekulovic

 

Task force for access to innovation in skin cancer. Access to innovative medicines for metastasic melanoma and non-melanoma skin cancer in Europe and worldwide - update 2017

L. Kandolf-Sekulovic

 

ESMO initiatives for better access to medicines

J. Tabernero

 

Improving cancer patients' outcomes - a collaborative approach

A. Roediger

 

EU options for improving access to medicines

Speaker to be confirmed

 

Cancer patients' associations initiatives to influence reimbursement decision making in Europe and worldwide

B. Ryll

 

How to improve the access to innovative medicines in Europe?

Panel discussion

09:00-10:00

SYMPOSIUM 12

Management of cutaneous toxicities

Chairs: B. Dréno - C. Lebbé

 

BRAF +MEK (combination) inhibitors

C. Dessinioti

 

Immune check point inhibitor

B. Dréno

 

Hedgehog inhibitor

I. Zalaudek

 

Anti EGF

C. Lebbé

 

 

SYMPOSIUM 13

Melanoma biology and genetics

Chairs: V. Bataille - R. Scolyer

 

Melanoma genomics

R. Scolyer

 

Imaging and treating pre-metastasic niches in melanoma

M. Soengas

 

The role of UV in elderly melanoma patients

A. Viros

 

Microbiome and melanoma susceptibility

V. Bataille

 

Spitzoid tumours

J. Bauer

BREAKOUT SESSION 5

Running a skin cancer centre

Chairs:  G. Long - V. Sondak -

L. Thomas

 

 

 

 

 

 

 

 

 

 

 

 

FREE

COMMUNICATIONS II

Chairs: C. Harwood - J. Oláh - A. Toll

10:00-10:30 Coffee break - visit to the Exhibition & e-poster viewing
10:30-11:30

INDUSTRY SATELLITE SYMPOSIUM - AMGEN GmbH

Turning viruses against melanoma

 

Welcome and introduction

J. Malvehy

 

Which patients to treat with an intralesional oncolytic virus in melanoma

P. Mohr

 

Expanding the possibilities for oncolytic viruses with checkpoint inhibitors

O.Michielin

 

Future perspectives on oncolytic immunotherapy-panel discussion and Q & A

J. Malvehy

     
11:30-11:45

Report of BREAKOUT SESSIONS 3-5

Chairs: J.E. Gershenwald -

L. Kandolf-Sekulovic -

L. Thomas

 

   
11:45-12:30

PLENARY  LECTURES II

Chairs: S. Puig - C. Robert

 

How to combine target and immunotherapy?

G. Long

 

Can we cure advanced metastasic melanoma patients?

A. Haushild

     
12:45-13:45

INDUSTRY SATELLITE LUNCH SYMPOSIUM  

PIERRE FABRE ONCOLOGY

How do we improve treatment outcomes of patients with BRAF-positive metastasic melanoma?

Chairs: A. Arance - A. Hauschild

 

Welcome and introduction

A. Arance, A. Hauschild

 

What is new for your patients with BRAF-positive metastasic melanoma?

M. Mandalà

 

What are your key considerations when choosing targeted therapy to treat patients with BRAF-positive metastasic melanoma?

A. Hauschild

 

Panel's perspective: an open discussion

All (chaired by A. Arance)

 

Summary and conclusion

A. Arance, A. Hauschild

     
14:00-15:00  

SYMPOSIUM 14

Local therapies in melanoma
Chairs: R. Andtbacka - B. Weide

 

Mechanisms of action of intralesional therapies

J. Becker

 

IL-2 and mRNA as intralesional approaches

B. Weide

 

Intralesional combination therapies

M. Ross

 

Intralesional therapies - modifiers of the tumour microenvironment

R. Andtbacka 

 

SYMPOSIUM 15

Combination therapies
Chairs: J. Larkin - C. Robert

 

Who should we treat with combo ipi + nivo in the clinic?

J. Larkin

 

ICPI + Targeted therapy combinations: we can but should we?

C. Robert

 

Emerging ICPI combos: clinical prospects: e.g. anti-PD1 + IDO, anti-PD1 +TVEC etc

C. Lebbé

 

The future: moving away from empirical and towards rational combinations

A. Ribas

SYMPOSIUM 16

Brain mets
Chairs: B. Dreno - T.K. Eigentler

F. Meier

 

Monoclonal antibodies in brain metastases

B. Dréno

 

Targeted therapy in brain metastases

T. K. Eigentler

 

Radiation plus targeted/immune therapy: what is known from retrospective studies?

F. Meier

 

Upfront radiosurgery followed by targeted or immune therapy-the Aix-Marseille University experience

J.J. Grob

 

15:15-16:15

INDUSTRY SATELLITE SYMPOSIUM - NOVARTIS

New treatments, new questions: practical considerations for implementing effective treatment strategies in melanoma

     
16:15-16:45 Coffee break - visit to the Exhibition & e-poster viewing
16:45-17:45

SYMPOSIUM 17

Immunotherapy of advanced melanoma

Chairs: C. Blank - R. Dummer

C. Robert

 

Neo-adjuvant therapy for early stage melanoma

C. Blank

 

Precision immunotherapy: dream or reality

R. Dummer

 

Involvement of protein translation control in response to Immunotherapy

C. Robert

 

Rare AE during IT-

L. Heinzerling

SYMPOSIUM 18

Predictive biomarkers

Chairs: C. Höller - O. Michielin

 

Principles of biomarker research

R. Dummer

 

Predictive biomarkers for stage IV immuno

therapies

O. Michielin

 

Predictive biomarkers for stage IV targeted

therapies

C. Höller

 

Predictive biomarkers for adjuvant

therapies?

P. Lorigan

WORKSHOP 3

Sentinel lymph node biopsy. Indications and surgic procedure

Chair: D. Moreno-Ramírez

 

Current indications of SLNB in dermato-oncology

R. Kaufmann

 

Mapping and navigation of he SLN

S. Vidal-Sicart

 

SLNB surgical technique

R. Vieira

 

Learning and training of the SLNB D. Moreno-Ramírez

FREE COMMUNICATIONS III

Chairs A. Arance - A. Boada

17:45-18:45

WORKSHOP 4

Evaluation of field cancerisation (AKASI method)

 

 

 

 

AUDITORIUM

MEETING ROOM 1 MEETING ROOM 2 MEETING ROOM 3
08:30-09:15

SYMPOSIUM 19
Lymphoma
Chairs: T. Estrach - E. Guenova - R. Stadler

 

How to recognise and treat early mycosis fungoides

E. Guenova

 

Targeted Therapies in cutaneous lymphomas

R. Stadler

 

Large scale collaborative data-base driven clinical research in CTCL and PROCLIPI update

J. Scarisbrick

     
09:15-10:00

SYMPOSIUM 20 
Rare malignant skin tumoirs

Chairs: J. Olàh - P. Saig

 

Other rare cutaneous neoplasms

J. Oláh 

 

Dermatofibrosarcoma

P. Saiag

 

Merkel/Kaposi sarcoma

C. Lebbé 

     
10:00-10:30 Coffee Break - Visit to Exhibition & e-poster viewing      
10:30-12:30

PLENARY LECTURES III

Chairs: C. Garbe - D. Whitaker

 

The emerging era of no completion lymph node dissection

D. Coit

 

Skin cancer in black skin

D. Whitaker

 

The future of immunotherapy

C. Robert

 

Future developments in melanoma treatment

A. Ribas

     
12:30-12:45 CLOSING CEREMONY AND AWARDS      

Secretary

SBC servicios básicos de congresos
Mont-Roig, 13 Atc 2a
08006 Barcelona
Tel. +34 933685538
Fax +34 933685829
www.sbc-congresos.com
info@sbc-congresos.com